Widely used:Recently Viewed
Clear All
$2,663 Mln
--
5.22
--
0
-27.95 %
--
0 %
5.45
-1538349
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Edgewise Therapeutics (EWTX)
| 159.60 | 58.84 | 55.36 | 387.97 | 17.43 | -- | -- |
|
BSE Sensex*
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
|
|---|---|---|
|
Edgewise Therapeutics (EWTX)
| 22.37 | -41.49 |
|
S&P Small-Cap 600
| 13.89 | -17.42 |
|
BSE Sensex
| 18.74 | 4.44 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$2,663.13 Mln
$2.25 Mln
$0.00 Mln
$511.75 Mln
$4.99 Mln
High
$5.12 - 30.00
93,772,304
NASDAQ: EWTX
Boulder, CO
https://www.edgewisetx.com
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II... clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado. Read more
The total asset value of Edgewise Therapeutics Inc (EWTX) stood at $ 549 Mln as on 30-Jun-24
The share price of Edgewise Therapeutics Inc (EWTX) is $28.40 (NASDAQ) as of 04-Oct-2024 16:20 EDT. Edgewise Therapeutics Inc (EWTX) has given a return of 17.43% in the last 3 years.
Edgewise Therapeutics Inc (EWTX) has a market capitalisation of $ 2,663 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Edgewise Therapeutics Inc (EWTX) is 5.22 times as on 04-Oct-2024, a 67% premium to its peers’ median range of 3.12 times.
Since, TTM earnings of Edgewise Therapeutics Inc (EWTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Edgewise Therapeutics Inc (EWTX) and enter the required number of quantities and click on buy to purchase the shares of Edgewise Therapeutics Inc (EWTX).
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
The CEO & director of Dr. Peter A. Thompson FACP, M.D.. is Edgewise Therapeutics Inc (EWTX), and CFO & Sr. VP is Dr. Peter A. Thompson FACP, M.D..
There is no promoter pledging in Edgewise Therapeutics Inc (EWTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Edgewise Therapeutics Inc. (EWTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-27.95
|
|
Operating margin(%)
|
-6066.7
|
|
Net Margin(%)
|
-5145.56
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Edgewise Therapeutics Inc (EWTX) was $0 Mln.
$1.77
